Drug intelligence / Profile preview

ABI-2280

Development stage
Phase 2
Lead developer
Antiva Biosciences
Modality
Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
Administration
Topical, Vaginal
01

Overview

ABI-2280 is a small molecule, topical prodrug of an acyclic nucleoside phosphonate developed by Antiva Biosciences. It is designed as a vaginal insert for the treatment of high-grade cervical intraepithelial neoplasia (CIN 2,3) and persistent high-risk human papillomavirus (HPV) infection. The drug acts through a dual mechanism—directly inhibiting human intracellular DNA polymerases required for HPV replication and inducing apoptosis in HPV-infected cells while sparing normal cells. This targeted approach provides both anti-proliferative and antiviral effects across all genotypes of HPV[1][2][3][5][8].

Other names
acyclic nucleoside phosphonate prodrug
02

Targets

POLA1 (DNA polymerase alpha)

Beyond the preview

Go deeper on ABI-2280.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABI-2280.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call